Clovis Oncology, Inc. (CLVS) |
0.0812 0 (0%) 12-20 16:00 |
Open: | 0.0808 |
High: | 0.0977 |
Low: | 0.078 |
Volume: | 24,212,259 |
Market Cap: | 0(M) |
PE Ratio: | -0.04 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 0.17 |
Resistance 1: | 0.13 |
Pivot price: | 0.10 |
Support 1: | 0.07 |
Support 2: | 0.06 |
52w High: | 3.25 |
52w Low: | 0.0422 |
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
EPS | -2.084 |
Book Value | -2.890 |
PEG Ratio | 0.00 |
Gross Profit | 0.795 |
Profit Margin (%) | -189.37 |
Operating Margin (%) | -155.16 |
Return on Assets (ttm) | -30.2 |
Return on Equity (ttm) | 0.0 |
Mon, 22 Apr 2024
Clovis Oncology Announces Second Quarter 2021 Operating Results - The Globe and Mail
Mon, 22 Apr 2024
Why Clovis Oncology Zoomed 30% Higher Today - The Globe and Mail
Mon, 22 Apr 2024
Why Clovis Oncology Stock Is Crushing It Today - The Globe and Mail
Mon, 22 Apr 2024
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast ... - The Globe and Mail
Sat, 20 Apr 2024
Company News For Oct 3, 2018 - Yahoo Movies UK
Mon, 12 Dec 2022
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy - Markets Insider
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |